GlassScriptPhysician profile
James Michael Liang
NPI 1043263387
$784.08
in general payments reported to CMS, 2019-2025
19 companies · $558 in 2025
The $558 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.77 · 2024: $211 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $118.55 | 2025 | Talvey, Darzalex, Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $95.06 | 2024-2025 | |
| Lilly USA, LLC | $90.74 | 2024-2025 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $89.47 | 2024-2025 | Enhertu, Injectafer |
| Servier Pharmaceuticals LLC | $46.57 | 2024-2025 | |
| Sobi, INC | $40.89 | 2024-2025 | |
| Emd Serono, INC. | $32.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.45 | 2024 | |
| Genentech USA, INC. | $25.38 | 2025 | Venclexta |
| Eisai INC. | $24.98 | 2024 | |
| Exelixis INC. | $24.45 | 2025 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $24.15 | 2025 | Empaveli |
| Celltrion USA INC. | $24.12 | 2025 | Vegzelma |
| Stemline Therapeutics INC. | $23.65 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $23.47 | 2025 | Jemperli, Zejula |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.65 | 2025 | Opdivo |
| Menarini Silicon Biosystems, INC. | $18.33 | 2025 | |
| Pharmacosmos Therapeutics INC. | $16.59 | 2025 | Monoferric |
| Janssen Pharmaceuticals, INC | $14.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.